Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials
| العنوان: | Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials |
|---|---|
| المؤلفون: | Jan Walewski, Michael Unterhalt, Christian H. Geisler, Michael Hallek, Martin Dreyling, J.K. Doorduijn, B. van der Holt, Vincent Ribrag, Anna Laurell, Johanna Kluin-Nelemans, Gilles Salles, Arne Kolstad, Wolfram Klapper, Mats Jerkeman, Michal Szymczyk, Christiane Pott, M. B. Van't Veer, R. Raty, Eva Hoster, Johannes Bloehdorn, Olivier Hermine |
| المساهمون: | Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), University Hospital Schleswig-Holstein, Department of Medicine, Helsinki University Central Hospital, III. Medizinische Klinik, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Technische Universität München [München] (TUM), Hematology, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL) |
| المصدر: | Leukemia Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2016, 30, pp.1428-1430. ⟨10.1038/leu.2015.322⟩ Leukemia, 30(6), 1428-1430. Nature Publishing Group |
| بيانات النشر: | Nature Publishing Group, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Melphalan, Oncology, Cancer Research, medicine.medical_specialty, Lymphoma, BEAM, [SDV.CAN]Life Sciences [q-bio]/Cancer, IMMUNOCHEMOTHERAPY, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Internal medicine, Germany, medicine, Registries, Etoposide, ComputingMilieux_MISCELLANEOUS, PROGNOSTIC INDEX, Carmustine, business.industry, Cytarabine, Hematology, Total body irradiation, RESCUE, medicine.disease, 3. Good health, Surgery, 030220 oncology & carcinogenesis, SURVIVAL, Medicine, Mantle cell lymphoma, epidemiology, pathology, France, business, Chemoradiotherapy, 030215 immunology, medicine.drug |
| الوصف: | In patients with mantle cell lymphoma (MCL) up to 65 years, recommended first-line treatment consists of immuno-chemotherapy including high-dose cytarabine (HA), followed by autologous stem cell transplantation (ASCT) in complete (CR) or partial remission (PR).1 However, it remains unclear whether total body irradiation (TBI) should be part of conditioning before ASCT.1 A large registry study by the European Society for Blood and Marrow Transplantation (EBMT) including 418 MCL patients reported a significantly reduced relapse incidence after TBI in comparison to a non-TBI conditioning (mostly carmustine, etoposide, cytarabine, and melphalan, BEAM), but only for patients transplanted in first PR.2 In contrast, a single-center evaluation of 73 MCL patients who underwent ASCT did not find a significant PFS difference according to the use of TBI vs BEAM.3 A recently published consensus project by EBMT/European MCL Network involving twelve expert clinicians showed that, while consensus was achieved on ASCT as standard first-line consolidation therapy, no consensus was reached on the role of TBI.4 Three recently completed prospective studies including untreated MCL patients up to 65 years investigated the efficacy of HA-containing immuno-chemotherapy followed by ASCT: Nordic MCL2,5, 6 HOVON-45(ref. 7) and European MCL Younger.8, 9 We combined the individual patient data from these studies to compare the long-term clinical outcome of MCL patients transplanted without TBI (Nordic MCL2 and HOVON-45) vs with TBI (MCL Younger, experimental HA-containing arm). |
| تدمد: | 1476-5551 0887-6924 |
| DOI: | 10.1038/leu.2015.322 |
| DOI: | 10.1038/leu.2015.322⟩ |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4225c03e70c112a3637b53d16d49a26f https://doi.org/10.1038/leu.2015.322 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4225c03e70c112a3637b53d16d49a26f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765551 08876924 |
|---|---|
| DOI: | 10.1038/leu.2015.322 |